Cleveland Review of Rheumatic Diseases 2026

Cleveland Review of Rheumatic Diseases 2026 is organized by University Hospitals (UH) Cleveland Medical Center and will be held from May 01 - 02, 2026 at Tinkham Veale University Center, Cleveland, Ohio, United States of America.

Learning objectives:
At the conclusion of this symposium, participants will be able to:

1. Describe the mechanisms, clinical evidence, and safety considerations of emerging therapies for scleroderma, with a focus on novel chimeric antigen receptor (CAR) T-cell therapy, including its application in refractory systemic sclerosis, patient selection, efficacy in organ and skin involvement, and current limitations and future directions.
2. Summarize recent updates in rheumatoid arthritis treatment, including biosimilars, new treatment modalities, new drug approvals, updated guidelines, and personalized medicine approaches.
3. Outline current best practices for treating connective tissue disease–associated interstitial lung disease (CTD-ILD), including antifibrotics, immunosuppressants, and emerging targeted therapies.
4. Evaluate emerging therapies in lupus and vasculitis, including new biologics, small molecules, and cell-based therapies, and their impact on disease control and patient outcomes.
5. Update knowledge in axial spondyloarthritis, including new modalities and treatments that improve long-term outcomes and quality of life.
6. Describe the utility of musculoskeletal ultrasound in rheumatology, including its role in diagnosis, disease monitoring, and guiding interventions in conditions such as Sjögren’s syndrome, psoriatic arthritis, and rheumatoid arthritis.
7. Discuss the potential utility of GLP-1 receptor agonists in autoimmune rheumatic diseases, focusing on mechanisms, metabolic and inflammatory effects, and emerging clinical data.
8. Recognize strategies for managing difficult-to-treat rheumatic diseases, emphasizing refractory cases, the integration of novel therapies, and individualized patient-centered approaches.
9. Identify and manage dermatologic and ophthalmologic manifestations of rheumatic diseases, understanding their diagnostic significance, systemic implications, and targeted treatment options.